Relay Therapeutics Q1 2024 GAAP EPS $(0.62) Beats $(0.71) Estimate, Sales $10.007M Beat $87.500K Estimate
Relay Therapeutics Q1 2024 GAAP EPS $(0.62) Beats $(0.71) Estimate, Sales $10.007M Beat $87.500K Estimate
Relay Therapeutics2024年第一季度GAAP每股收益美元（0.62美元）超过预期（0.71美元），销售额10007万美元超过预期的8750万美元
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.71) by 12.68 percent. This is a 20.51 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $10.007 million which beat the analyst consensus estimate of $87.500 thousand by 11.34K percent. This is a 4.33K percent increase over sales of $226.000 thousand the same period last year.
Relay Therapeutics（纳斯达克股票代码：RLAY）公布的季度亏损为每股0.62美元，比分析师普遍预期的0.71美元（0.71美元）高出12.68％。这比去年同期每股亏损0.78美元（0.78美元）增长了20.51％。该公司公布的季度销售额为1000.7万美元，比分析师普遍预期的87,500美元高出11.34万个百分点。这比去年同期的22.6万美元销售额增长了43.3万个百分点。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。